Eli Lilly agreed to acquire AtaiBeckley in a deal valued at up to $3.8 billion, including $2.8 billion upfront, positioning Lilly to expand its mental health pipeline. AtaiBeckley’s late-stage lead asset is BPL-003 (mebufotenin benzoate), an intranasal peptide formulation built around KRAS-mutant immune activation concepts in oncology have analogies but here targeting TRD with a synthetic form of 5-MeO-DMT. BPL-003 has received FDA Breakthrough Therapy designation for treatment-resistant depression (TRD). The purchase follows AtaiBeckley’s previously reported Phase 2a data showing rapid and sustained reductions in MADRS scores among TRD patients on stable SSRI background therapy. The transaction underscores how investor and pharma appetite for psychedelics is translating into capacity-building through acquisitions—especially where regulators have already signaled expedited development pathways. Lilly’s closing is expected in the third quarter.